[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pleural-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pleural-diseases":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,72,93,114,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100573097","confocal-laser-endomicroscopy-guided-medical-thoracoscopy-for-the-diagnosis-of-pleural-disease-100573097",false,"NCT06741839","Confocal Laser Endomicroscopy Guided Medical Thoracoscopy for the Diagnosis of Pleural Disease","Efficacy and Safety of Confocal Laser Endomicroscopy Guided Medical Thoracoscopy for the Diagnosis of Pleural Disease: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Evidence of exudative pleural effusion in which a specific diagnosis could not be determined using clinical, radiological, laboratory, or cytological examinations\n* Willingness to participate in the study and undergo an invasive procedure.;\n\nExclusion Criteria:\n\n* Pleural thickening or pleural-based mass without pleural effusion on radiologic examination;\n* Hemodynamic instability;\n* Presence of parapneumonic effusion;\n* Any contraindication to pleural biopsy or semirigid thoracoscopy;\n* Participation in other studies within three months without withdrawal or termination.","ALL","18 Years",{"count":19,"type":20},158,"ESTIMATED","INTERVENTIONAL",[23],"NA","A prospective multicenter randomized controlled trial was conducted to evaluate the efficacy and safety of thoracoscopic biopsy guided by confocal optical real-time microscopic imaging (nCLE) in the diagnosis of fibrinal pleurisy of unknown etiology. Patients with fibrinous pleurisy of unknown etiology who were to undergo thoracoscopic pleural biopsy were enrolled and informed consent was signed. Subjects were randomized to either the nCLE guided biopsy Group (Group A) or the visual biopsy group (Group B) according to the randomization table (1:1 ratio). nCLE was used to probe the benign and malignant status of pleural lesions, compare the consistency of random pathological biopsy or nCLE guided biopsy with histopathological results, compare whether nCLE guided biopsy can reduce the number of thoracoscopic biopsies, and follow up short-term postoperative complications to evaluate its safety.",[26,27],"Pleural Diseases","Pleural Effusion","RECRUITING","2026-04-11",{"date":31,"type":32},"2026-04-15","ACTUAL",{"date":34,"type":32},"2025-03-11",{"date":36,"type":20},"2027-05",{"name":38,"class":39},"China-Japan Friendship Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":40},"100576806","phase-2-the-diagnostic-accuracy-and-clinical-value-of-fapi-pet-in-pleural-mesothelioma-100576806","NCT06790082","The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma","FAPI PET in Pleural Mesothelioma: The Diagnostic Accuracy and Clinical Value of FAPI PET at Diagnosis, Primary Staging, and the Feasibility of FAPI PET for Response Evaluation","FAPI-PM","Inclusion Criteria:\n\n* Patients with pleural lesions suspicious of pleural mesothelioma and referred to pleural biopsy.\n* Undergone\u002Fundergoing FDG PET\u002FCT as part of the diagnostic workup of a suspicious PM lesion.\n* Considered physically and mentally able to participate in the research project.\n* Understands the study subject information and able to consent to project participation.\n* 18-years or older\n\nExclusion Criteria:\n\n* Patients with an imminent need for surgery or in an emergency\n* Known concurrent other malignancy with active treatment within the last 1 year; non-melanoma skin cancer and cervical cancer in situ are exempt.\n* Pregnant or breastfeeding women.\n* Fertile women (women of childbearing potential) who could - theoretically - be pregnant (i.e., unknown pregnancy status).\n\nFertile women will be tested for pregnancy (by urine humane choriogonadotropin (HCG) or serum HCG) within 48h before FAPI PET\u002FCTs, both at primary staging and restaging. Study subjects can participate in the study if the pregnancy test is negative (i.e., not pregnant).\n\n* Subjects unable to undergo PET\u002FCT: e.g., weighing more than 180 kg (weight limit scanner), unable to fit within the imaging gantry, inability to remain still for the duration of the examination, or with known severe claustrophobia unresponsive to oral anxiolytics or severe fear of needles.\n* Subjects with any medical condition or other circumstances that, in the opinion of the Investigator, would significantly decrease the reliability of data, achievement of study objectives or completing the study.\n* History of allergic reactions \u002F hypersensitivity attributed to \\[18F\\]FDG or FAPI-tracers.",{"count":50,"type":20},70,[52],"PHASE2","Seventy (N=70) patients with suspected pleural mesothelioma (PM) lesions referred to pleural biopsy will be recruited, and undergo an additional FAPI PET\u002FCT at primary staging.\n\nThe FAPI PET\u002FCT results will be compared to conventional imaging (including FDG PET\u002FCT). The diagnostic accuracy will be determined with histopathology as reference standard.\n\nFor patients undergoing anticancer treatment (chemotherapy, immunotherapy, other treatment), an additional FAPI PET\u002FCT and an additional FDG PET\u002FCT will be conducted after the study subjects have completed 2-3 series of anticancer treatment. The feasabilitiy of FAPI PET\u002FCT in response evaluation will be investigated.\n\nAll study specific analyzes will be blinded and will not influence the patient management \u002F treatment.",[55,26,56,57,58],"Pleural Mesothelioma","Cancer","FAPI","Fibroblast Activation Protein Inhibitor",[57,60,61,55,62],"68Ga-FAPI-46","PET\u002FCT","FDG PET\u002FCT","2025-07-01",{"date":65,"type":32},"2025-07-03",{"date":67,"type":32},"2025-01-29",{"date":69,"type":20},"2037-04-30",{"name":71,"class":39},"Aalborg University Hospital",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":40},"100590199","thoracoscopic-pleural-biopsy-in-sohag-university-hospital-100590199","NCT06964308","Thoracoscopic Pleural Biopsy in Sohag University Hospital","Thoracoscopic Pleural Biopsy, Sohag University Hospital","Inclusion Criteria:\n\n* Patients with suspected pleural disease who have been referred for thoracoscopic pleural biopsy\n* Age: Adults aged 18 years and older\n* Patients should have undergone necessary preoperative evaluations, including imaging studies (e.g., chest X-ray, CT scan) that indicate a need for biopsy.\n\nExclusion Criteria:\n\n* Contraindications to Thoracoscopic Biopsy: Patients with contraindications to thoracoscopic biopsy\n* Infeasibility of Procedure: Patients with anatomical or physiological factors that make thoracoscopic biopsy technically unfeasible or unsafe (e.g., severe pleural adhesions or distorted anatomy).\n* Alternative Diagnoses: Patients who have been definitively diagnosed with a condition that does not require thoracoscopic biopsy for further evaluation.\n* Pregnancy: Pregnant women may be excluded due to potential risks to the fetus and the need for specific procedural considerations.\n* Inability to Provide Consent: Patients who are unable to provide informed consent due to cognitive impairment, language barriers, or other reasons.\n* Participation in Concurrent Studies: Patients currently participating in other clinical studies that could interfere with the outcomes of this study or affect their eligibility.",{"count":80,"type":20},36,[23],"This study aims to evaluate the diagnostic efficacy, safety, and clinical outcomes of thoracoscopic pleural biopsy in the management of pleural diseases.",[26],"2025-04-30",{"date":86,"type":32},"2025-05-09",{"date":88,"type":32},"2024-10-01",{"date":90,"type":20},"2025-05-30",{"name":92,"class":39},"Sohag University",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":40},"100573318","dual-function-semirigid-thoracoscopy-versus-semirigid-thoracoscopy-for-the-diagnosis-of-pleural-diseases-a-multicenter-open-label-randomized-controlled-trial-100573318","NCT06744725","Dual-function Semirigid Thoracoscopy Versus Semirigid Thoracoscopy for the Diagnosis of Pleural Diseases: A Multicenter Open-label Randomized Controlled Trial","Dual-function Semirigid Thoracoscopy Versus Semirigid Thoracoscopy for the Diagnosis of Pleural Diseases: A Protocol for a Multicenter Open-label Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Unilateral pleural effusion of unclear etiology after a less invasive diagnosis\n* Fully informed of the purpose and method of the study, agreed to participate in the study, and signed an informed consent form.\n\nExclusion Criteria:\n\n* PaO2\u002FFiO2 \\\u003C 300\n* Tendency for uncontrolled bleeding, unstable cardiovascular status, or severe heart failure\n* A complete pleural symphysis, where it is not possible to create a pneumothorax\n* Refractory cough\n* Eastern Cooperative Oncology Group performance status 4\n* Disagreements regarding study participation\n* Participation in other studies within three months without withdrawal or termination.",{"count":101,"type":20},334,[23],"We designed and developed a novel dual-function semirigid thoracoscope (UE FET-680; UE Corporation, Zhejiang, China) with a straight channel adapted to flexible and rigid forceps for pleural biopsy. Our preclinical trial has proven that the dual-function semirigid thoracoscope has larger and deeper sampling while retaining the entire thoracic accessibility and flexible bronchoscopic maneuvering habits of the semirigid thoracoscope. We designed this study to directly compare the diagnostic yield, quality of sampling, and safety between the dual-function semirigid thoracoscope and semirigid thoracoscope.",[26],"NOT_YET_RECRUITING","2024-12-19",{"date":108,"type":32},"2024-12-20",{"date":110,"type":20},"2025-01-01",{"date":112,"type":20},"2026-01-01",{"name":38,"class":39},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":21,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":5},"100529963","strategy-for-prompt-and-effective-thoracentesis-in-the-emergency-department-100529963","NCT06180603","Strategy for Prompt and Effective Thoracentesis in the Emergency Department","Strategy for Prompt and Effective Thoracentesis in the Emergency Department: A Multicenter Randomized Clinical Trial","SPEEDTAP","Inclusion Criteria:\n\n* Patients ≥ 18 years admitted to the ED\n* Pleural effusion detected by any imaging modality (e.g., bedside ultrasound, chest x-ray, computed tomography)\n* Clinically justified need for thoracentesis ( symptomatic relief and\u002For define the etiology of the effusion\n* Without contraindication for thoracentesis in the emergency department (e.g., anticoagulant treatment)\n\nExclusion Criteria:\n\n* Life-threatening respiratory distress\n* Not able to give consent\n* Previous pleurodesis\n* Effusion does not appear free-flowing due to septations or loculations \u002F suspected empyema\n* Prior enrollment in the trial\n* If randomization is not possible because decision to insert a pigtail catheter is made in the radiology department",{"count":123,"type":20},188,[23],"The SPEEDTAP-trial is a prospective, randomised, investigator-initiated, multicenter, clinical superior trial investigating two thoracentesis methods in four emergency departments (ED) in Central Denmark Region. Patients are randomised to either manual fluid removal in the ED or passively fluid drainage using gravity in the radiology department (standard of care). Primary outcome: time from clinical indication to complete drainage and 188 patients will be included. Key secondary outcomes include length of stay, ED admission to ED discharge and safety end-points.",[27,26,127],"Heart Failure",[129,130,131],"Thoracentesis","Emergency department","Treatment methods","2024-12-04",{"date":134,"type":32},"2024-12-05",{"date":136,"type":32},"2024-01-15",{"date":138,"type":20},"2025-12-31",{"name":140,"class":39},"University of Aarhus",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":159,"locationsCount":40},"100533522","the-efficacy-of-shear-wave-elastography-guided-biopsy-for-diagnosis-in-pleural-disease-100533522","NCT06226909","The Efficacy of Shear-wave Elastography-guided Biopsy for Diagnosis in Pleural Disease","The Efficacy of Shear-wave Elastography-guided Biopsy for Diagnosis in Pleural Disease: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with radiographic evidence of pleural disease\n\nExclusion Criteria:\n\n* Age \\\u003C 18 y\u002Fo\n* Patients who cannot hold their breath for 5 seconds",{"count":149,"type":20},234,[23],"To investigate the information from shear-wave elastography on pleural tissues will improve the diagnosis of pleural diseases, as to increase the diagnostic yield in ultrasound-guided transthoracic pleura biopsy.",[26],"2024-01-30",{"date":155,"type":32},"2024-02-01",{"date":136,"type":32},{"date":158,"type":20},"2027-08-31",{"name":160,"class":39},"National Taiwan University Hospital"]